InsiderTrades.com logo
Will this $2 AI stock double overnight?
From Behind the Markets   |   Ad
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Click here to learn more >>>
Terry J. Rosen net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Terry Rosen Biography and Net Worth

CEO of Arcus Biosciences
Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression

What is Terry J. Rosen's net worth?

The estimated net worth of Terry J. Rosen is at least $3.74 million as of December 16th, 2022. Dr. Rosen owns 242,173 shares of Arcus Biosciences stock worth more than $3,736,729 as of April 24th. This net worth approximation does not reflect any other investments that Dr. Rosen may own. Additionally, Dr. Rosen receives an annual salary of $756,110.00 as CEO at Arcus Biosciences. Learn More about Terry J. Rosen's net worth.

How old is Terry J. Rosen?

Dr. Rosen is currently 64 years old. There are 6 older executives and no younger executives at Arcus Biosciences. The oldest executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co- Founder & President, who is 66 years old. Learn More on Terry J. Rosen's age.

What is Terry J. Rosen's salary?

As the CEO of Arcus Biosciences, Inc., Dr. Rosen earns $756,110.00 per year. There are 2 executives that earn more than Dr. Rosen. The highest earning executive at Arcus Biosciences is Dr. Juan Carlos Jaen Ph.D., Co- Founder & President, who commands a salary of $931,140.00 per year. Learn More on Terry J. Rosen's salary.

How do I contact Terry J. Rosen?

The corporate mailing address for Dr. Rosen and other Arcus Biosciences executives is 3928 Point Eden Way, Hayward CA, 94545. Arcus Biosciences can also be reached via phone at (510) 694-6200 and via email at [email protected]. Learn More on Terry J. Rosen's contact information.

Has Terry J. Rosen been buying or selling shares of Arcus Biosciences?

Terry J. Rosen has not been actively trading shares of Arcus Biosciences during the last ninety days. Most recently, Terry J. Rosen sold 13,043 shares of the business's stock in a transaction on Friday, December 16th. The shares were sold at an average price of $30.75, for a transaction totalling $401,072.25. Following the completion of the sale, the chief executive officer now directly owns 242,173 shares of the company's stock, valued at $7,446,819.75. Learn More on Terry J. Rosen's trading history.

Who are Arcus Biosciences' active insiders?

Arcus Biosciences' insider roster includes Robert Goeltz II (CFO), Juan Jaen (President), Jennifer Jarrett (COO), Terry Rosen (CEO), and Carolyn Tang (General Counsel). Learn More on Arcus Biosciences' active insiders.

Are insiders buying or selling shares of Arcus Biosciences?

During the last twelve months, Arcus Biosciences insiders bought shares 2 times. They purchased a total of 16,248,095 shares worth more than $339,452,595.00. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 176,342 shares worth more than $3,417,282.87. The most recent insider tranaction occured on March, 27th when COO Jennifer Jarrett sold 11,551 shares worth more than $202,720.05. Insiders at Arcus Biosciences own 13.8% of the company. Learn More about insider trades at Arcus Biosciences.

Information on this page was last updated on 3/27/2024.

Terry J. Rosen Insider Trading History at Arcus Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2022Sell13,043$30.75$401,072.25242,173View SEC Filing Icon  
6/16/2022Sell4,241$20.72$87,873.52232,329View SEC Filing Icon  
12/16/2021Sell2,299$39.82$91,546.18View SEC Filing Icon  
6/6/2019Buy21,738$7.93$172,382.34View SEC Filing Icon  
6/4/2019Buy41,540$7.91$328,581.40View SEC Filing Icon  
8/28/2018Buy18,607$15.07$280,407.49View SEC Filing Icon  
8/24/2018Buy9,289$13.45$124,937.05View SEC Filing Icon  
8/21/2018Buy8,891$13.24$117,716.84View SEC Filing Icon  
8/16/2018Buy28,401$12.64$358,988.64View SEC Filing Icon  
8/13/2018Buy9,929$11.87$117,857.23View SEC Filing Icon  
3/19/2018Buy66,666$15.00$999,990.00View SEC Filing Icon  
See Full Table

Terry J. Rosen Buying and Selling Activity at Arcus Biosciences

This chart shows Terry J Rosen's buying and selling at Arcus Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arcus Biosciences Company Overview

Arcus Biosciences logo
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Read More

Today's Range

Now: $15.43
Low: $14.73
High: $15.85

50 Day Range

MA: $17.54
Low: $14.59
High: $20.18

2 Week Range

Now: $15.43
Low: $12.95
High: $25.47

Volume

524,078 shs

Average Volume

806,907 shs

Market Capitalization

$1.40 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81
Will this $2 AI stock double overnight?
From Behind the Markets   |   Ad
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Click here to learn more >>>